Q2 2026 marked clear reacceleration above the prior run-rate after the COVID-test revenue hangover

• Revenue: $11.99 billion, up 9.0% year-over-year
• Net income: $1.74 billion, up 7.4% YoY
• Diluted EPS: $4.68
• First quarter clearly showing reacceleration above the prior run-rate after the 2023 COVID-test-revenue hangover

↩ rebuts: “Bear framing TMO as a momentum stock rolling over”

Forward-looking consensus implies ~48% earnings expansion with mid-to-high teens underlying EPS growth

• TTM EPS: $18.57
• Forward EPS consensus: $27.53
• Implied ~48% earnings expansion on the books
• Mid-to-high teens underlying EPS growth

↩ rebuts: “Bear arguing the rally is exhausted”

TMO and Danaher are positioned to return to mid-single-digit organic revenue growth in 2027

• UBS upgrade thesis
• Post-COVID destocking trough behind us
• Biopharma R&D budgets normalizing

↩ rebuts: “Bear's 'consolidating stock with deteriorating momentum' framing”

TMO's competitive moat is structural with high switching costs

• Largest player globally in life sciences tools, diagnostics, and lab products
• Four diversified segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services
• No single end market can break this company
• Pharma is roughly 50%, other 50% spans biotech, clinical, academic, and applied markets

↩ rebuts: “Bear dismissing $8.87 billion Q1 2026 acquisition as 'increased leverage risk'”

The Olink proteomics acquisition extends TMO into a TAM compounding 15%+ annually

• $8.87 billion acquisition in Q1 2026 (Olink proteomics platform)
• Transformational addition extends TMO's reach into protein biomarker discovery
• TAM compounding 15%+ annually

↩ rebuts: “Bear dismissing the acquisition as goodwill bloat”

TMO's genomics-adjacent exposure is diversified enough to withstand PacBio weakness given Illumina's strong uptrend

• Illumina is in a strong uptrend
• TMO's genomics-adjacent exposure is far more diversified than a pure-play sequencing name

↩ rebuts: “Bear citing PacBio cutting 2026 guidance as a reason for caution on sequencing tools”

A 22x forward P/E on a compounder growing earnings at high-teens percent is reasonable, not premium

• Forward P/E: 22.0x
• TTM P/E: 32.6x (lagging indicator reflecting 2023-2024 trough earnings)
• PEG Ratio: 1.83
• At 52-week high of $647, TMO traded at a higher forward multiple than it does today at $605

↩ rebuts: “Bear characterizing TTM P/E of 32.6x as 'premium valuation'”

Net debt increase reflects capital allocation in action, not a red flag

• Net debt jumped to $38.49 billion in Q2 2026 from $29.53 billion at FY25
• Q2 2026 FCF: $1.68 billion
• Annual FCF runs $6-7 billion consistently
• Company still executing $3 billion in annual buybacks on top of dividend
• 1.55x current ratio

↩ rebuts: “Bear treating net debt increase as a red flag”

TMO's 0.85 beta means it historically outperforms in risk-off environments

• Beta of 0.854
• Limited direct oil input cost exposure
• Second-order effects only: freight costs and risk-off equity flows

↩ rebuts: “Bear's generic macro arguments (oil at $101/bbl, 93% probability of no Fed cuts in 2026)”

Soft landing consensus (8% recession probability by end of 2026) supports TMO's end markets

• Recession probability by end of 2026: 8%
• Biopharma R&D budgets hold up
• Clinical diagnostics volumes stay stable
• Academic/government lab spending continues

↩ rebuts: “Bear's recession risk argument”

Healthcare sector rotation into defensive, cash-flow-rich compounders is in early innings

• Healthcare is up 23.2% in six months
• Healthcare outperformed S&P by 11.5 percentage points
• Rotation into defensive, cash-flow-rich compounders still in early innings relative to broader risk-off setup

↩ rebuts: “Bear arguing healthcare rally may already be priced in”

MACD bearish crossover is a momentum-cooling signal, not a trend-reversal signal

• MACD is still positive in absolute terms at 9.97
• MACD histogram: -4.72
• 10.4% rally in 16 sessions from $574 to $633
• 4.4% pullback over 10 sessions is healthy profit-taking, not a structural breakdown

↩ rebuts: “Bear's MACD bearish crossover signal”

RSI cooled from overbought (>70) back to neutral (~53) is a bullish setup for the next leg

• RSI dropped from 75 to 52.86
• RSI cooled from overbought (>70) back to neutral (~53) without going oversold
• The oscillator has reset—this is exactly what you want to see before the next push higher

↩ rebuts: “Bear citing RSI drop as bearish”

Long-term technical structure is intact with price above rising 50 SMA and 200 SMA

• Price is 0.95% below the 10 EMA at $611
• Price is 5.5% above the 50 SMA at $574
• Price is 13% above the 200 SMA at $536
• 200 SMA has been rising for over a year, confirming the structural uptrend

↩ rebuts: “Bear citing price below 10 EMA as bearish”

Absence of retail interest is a positive—TMO is institutional money with no crowding

• No retail interest
• $224 billion market cap
• Institutional money accumulating through sell-side upgrades, not retail euphoria
• No crowding = more room to run

↩ rebuts: “Bear citing lack of retail interest as bearish”

Q3 2026 earnings (late October) could be a re-rating event if Q2's 9% revenue growth is sustained

• Q3 2026 earnings (late October)
• Q2's 9% revenue growth sustained
• Consensus forward EPS of $27.53 starts looking conservative
• Any upward revision is a re-rating event

↩ rebuts: “Bear anchoring on lack of immediate catalyst”

Olink integration commentary will quantify synergies and close the protein-biomarker TAM gap

• Management will start quantifying synergies
• This is the deal that closes the protein-biomarker TAM gap

↩ rebuts: “Bear not accounting for integration catalyst”

XBI recovery would validate 2027 organic-growth re-acceleration thesis

• XBI (biotech ETF) recovery
• Biotech capex is a coincident indicator for TMO's pharma/biotech end markets
• Sustained XBI recovery validates the 2027 organic-growth re-acceleration thesis

↩ rebuts: “Bear not accounting for coincident indicator catalyst”

Entry setup is compelling with 6.4% pullback from 52-week high compressing the forward multiple

• Stock is 6.4% off its high of $647
• Forward multiple is already compressing
• At $605, entry below the 52-week high provides better risk/reward

↩ rebuts: “Bear selling into the consolidation”